Polymeric Materials for Hemostatic Wound Healing
Hemorrhage is one of the greatest threats to life on the battlefield, accounting for 50% of total deaths. Nearly 86% of combat deaths occur within the first 30 min after wounding. While external wound injuries can be treated mostly using visual inspection, abdominal or internal hemorrhages are more challenging to treat with regular hemostatic dressings because of deep wounds and points of injury that cannot be located properly. The need to treat trauma wounds from limbs, abdomen, liver, stomach, colon, spleen, arterial, venous, and/or parenchymal hemorrhage accompanied by severe bleeding requires an immediate solution that the first responders can apply to reduce rapid exsanguinations from external wounds, including in military operations. This necessitates the development of a unique, easy-to-use, FDA-approved hemostatic treatment that can deliver the agent in less than 30 s and stop bleeding within the first 1 to 2 min at the point of injury without application of manual pressure on the wounded area..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Pharmaceutics - 13(2021), 12, p 2127 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Suvash Ghimire [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Blood |
|---|
| doi: |
10.3390/pharmaceutics13122127 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ084756438 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ084756438 | ||
| 003 | DE-627 | ||
| 005 | 20240414222928.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230311s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/pharmaceutics13122127 |2 doi | |
| 035 | |a (DE-627)DOAJ084756438 | ||
| 035 | |a (DE-599)DOAJ70840712aa944663b72046511db9e8b5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RS1-441 | |
| 100 | 0 | |a Suvash Ghimire |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Polymeric Materials for Hemostatic Wound Healing |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Hemorrhage is one of the greatest threats to life on the battlefield, accounting for 50% of total deaths. Nearly 86% of combat deaths occur within the first 30 min after wounding. While external wound injuries can be treated mostly using visual inspection, abdominal or internal hemorrhages are more challenging to treat with regular hemostatic dressings because of deep wounds and points of injury that cannot be located properly. The need to treat trauma wounds from limbs, abdomen, liver, stomach, colon, spleen, arterial, venous, and/or parenchymal hemorrhage accompanied by severe bleeding requires an immediate solution that the first responders can apply to reduce rapid exsanguinations from external wounds, including in military operations. This necessitates the development of a unique, easy-to-use, FDA-approved hemostatic treatment that can deliver the agent in less than 30 s and stop bleeding within the first 1 to 2 min at the point of injury without application of manual pressure on the wounded area. | ||
| 650 | 4 | |a polymer | |
| 650 | 4 | |a hemostasis | |
| 650 | 4 | |a blood | |
| 650 | 4 | |a wound | |
| 650 | 4 | |a nanoparticles | |
| 650 | 4 | |a metals | |
| 653 | 0 | |a Pharmacy and materia medica | |
| 700 | 0 | |a Pritha Sarkar |e verfasserin |4 aut | |
| 700 | 0 | |a Kasey Rigby |e verfasserin |4 aut | |
| 700 | 0 | |a Aditya Maan |e verfasserin |4 aut | |
| 700 | 0 | |a Santanu Mukherjee |e verfasserin |4 aut | |
| 700 | 0 | |a Kaitlyn E. Crawford |e verfasserin |4 aut | |
| 700 | 0 | |a Kausik Mukhopadhyay |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Pharmaceutics |d MDPI AG, 2010 |g 13(2021), 12, p 2127 |w (DE-627)DOAJ000114154 |x 19994923 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:12, p 2127 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/pharmaceutics13122127 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/70840712aa944663b72046511db9e8b5 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/1999-4923/13/12/2127 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1999-4923 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 12, p 2127 | ||